Last reviewed · How we verify
regional chemotherapy
Regional chemotherapy involves delivering high doses of chemotherapy directly to a specific area of the body, such as the liver, to treat cancer.
Regional chemotherapy involves delivering high doses of chemotherapy directly to a specific area of the body, such as the liver, to treat cancer. Used for Liver cancer, including hepatocellular carcinoma.
At a glance
| Generic name | regional chemotherapy |
|---|---|
| Sponsor | Delcath Systems Inc. |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This targeted approach allows for higher concentrations of chemotherapy to be delivered directly to the tumor site, reducing the impact on healthy tissues and minimizing systemic side effects. Regional chemotherapy is typically performed using a catheter or other device to isolate the treatment area.
Approved indications
- Liver cancer, including hepatocellular carcinoma
Common side effects
- Hepatotoxicity
- Infection
- Bleeding
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Splenic Artery Infusion Chemotherapy vs Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- regional chemotherapy CI brief — competitive landscape report
- regional chemotherapy updates RSS · CI watch RSS
- Delcath Systems Inc. portfolio CI